ARTES Biotechnology GmbH and NL Biotechnologies LLC join in a strategic collaboration and co-marketing alliance

06-Sep-2011 - ARTES Biotechnology and NL Biotechnologies started a strategic collaboration. With signing this collaboration agreement the two companies combine their know-how and technologies in yeast expression, process and vaccine development. The direct and noticeable aim is the marketing of efficient and ...

ARTES Steps Further Into the Vaccine Business by Acquiring Anavax

29-Sep-2010 - ARTES Biotechnology announced the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases. With the combination of two excellent technology platforms, ...

Q Chip and ARTES Biotechnology announce collaboration to develop sustained release formulations of therapeutic proteins

04-May-2010 - Q Chip Ltd and ARTES Biotechnology GmbH announced that they have signed a Collaborative Agreement to explore the development of a new sustained release formulations of interferon alpha 2a for the treatment of chronic hepatitis B and C. The collaboration aims to improve patient compliance and ...

ARTES and Rhein Minapharm continue their successful product development collaboration

17-Nov-2009 - ARTES Biotechnology and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE, jointly announced the successful production of a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies ...

ARTES and Minapharm sign long-term strategic development agreement

15-Jan-2008 - ARTES Biotechnology and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE jointly announced the start of a strategic collaboration to develop three therapeutic proteins. Financial details were not disclosed. ARTES will apply its proprietary Hansenula technology platform and know-how to ...

ARTES Biotechnology GmbH and ProteoNic BV start research collaboration

20-Jun-2006 - ARTES Biotechnology GmbH, Germany, and ProteoNic B.V., The Netherlands, announced the start of their research collaboration. Both companies will join forces to investigate on the application of ProteoNic´s proprietary technology for enhancement of gene expression in the methylotrophic yeast ...

Proteo Biotech AG Signs an Exclusive License- and Collaboration-Agreement with Artes Biotechnology GmbH

Leading Technology for the Recombinant Production of Elafin Worldwide Secured

10-Dec-2004 - Proteo Biotech is producing its Elafin with the patent protected yeast strain Hansenula polymorpha on a recombinant basis for a world market. PROTEO has signed an exclusive License- and collaboration agreement with ARTES Biotechnology GmbH. ,,This agreement will enable us to produce Elafin, in a ...